US20160317050A1 - Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient - Google Patents

Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient Download PDF

Info

Publication number
US20160317050A1
US20160317050A1 US14/545,377 US201514545377A US2016317050A1 US 20160317050 A1 US20160317050 A1 US 20160317050A1 US 201514545377 A US201514545377 A US 201514545377A US 2016317050 A1 US2016317050 A1 US 2016317050A1
Authority
US
United States
Prior art keywords
hdp
values
patient
monitoring system
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/545,377
Other languages
English (en)
Inventor
Federico Perego Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therabionic Inc
Original Assignee
Federico Perego Costa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federico Perego Costa filed Critical Federico Perego Costa
Priority to US14/545,377 priority Critical patent/US20160317050A1/en
Priority to JP2018508612A priority patent/JP7036712B2/ja
Priority to SG11201903784PA priority patent/SG11201903784PA/en
Priority to SG10201910005Q priority patent/SG10201910005QA/en
Priority to PCT/US2016/028880 priority patent/WO2016176117A1/en
Priority to CN201680038230.4A priority patent/CN108064147B/zh
Priority to EP16786952.8A priority patent/EP3288448A4/en
Priority to US15/569,312 priority patent/US10624546B2/en
Publication of US20160317050A1 publication Critical patent/US20160317050A1/en
Priority to HK18110471.7A priority patent/HK1250899A1/zh
Priority to US16/594,625 priority patent/US20200268258A1/en
Priority to US16/853,173 priority patent/US11589765B2/en
Assigned to AVATAR PARTNERS LIMITED reassignment AVATAR PARTNERS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COSTA, Frederico Perego
Assigned to THERABIONIC, INC. reassignment THERABIONIC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AVATAR PARTNERS LIMITED
Priority to US18/175,021 priority patent/US20230218188A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026—Measuring blood flow
    • A61B5/0265—Measuring blood flow using electromagnetic means, e.g. electromagnetic flowmeter
    • A61B5/0456—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle
    • A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment
    • A61N5/025—Warming the body, e.g. hyperthermia treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A61B5/02108—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A61B5/02141—Details of apparatus construction, e.g. pump units or housings therefor, cuff pressurising systems, arrangements of fluid conduits or circuits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/0245—Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/0255—Recording instruments specially adapted therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A61N5/022—Apparatus adapted for a specific treatment

Definitions

  • This invention relates to a hemodynamic parameter (Hdp) monitoring system for diagnosis, more particularly involving a monitor able to sense and monitor various specified Hdp values and providing recorded values thereof.
  • the recorded specified Hdp values include values required for purposes of performing diagnoses in terms of the invention.
  • Hdp monitors are available in the art. Such monitors are generally employed to sense and monitor various Hdp values, usually for purposes of diagnosing cardiovascular conditions of a patient. Hdp measurements performed, generally in conjunction with an electrocardiogram (ECG), might include measurements of stroke volume (SV), stroke index (SI) and cardiac output (CO). Such measurements are indicated for the diagnosis and therapy of patients suffering from cardiac conditions such as heart failure, hypertension, coronary artery disease, pericardial disease, obstructive lung and pleural disease and also renal insufficiency. So-called impedance cardiography (ICG), involving application of a fixed current (of about 400 microAmps at 40 kHz) to spaced apart electrodes is described in the literature for purposes of measuring actual patient current. This state of the art is essentially concerned with securing CO measurements and comparisons of the spaced electrode ICG procedure with well-known and regularly employed thermodilution (TD) procedures for measuring CO or calculating such by multiplying stroke volume (SV) with heart-rate (HR).
  • ECG
  • the present invention is essentially concerned with diagnosing a health condition of a patient
  • This disclosure does not contemplate or suggest employing measured Hdp values as a means for diagnosis of either a type of cancer or indeed any other form of a health condition of a patient.
  • Diagnosis in terms of the present invention may be performed with the aid of certain measured and recorded Hdp parameter values measured, in a number of patients pre-diagnosed to be suffering from an identified poor health condition or being in a healthy condition, at determined times and for determined periods, as described in greater detail below.
  • a hemodynamic parameter (Hdp) monitoring system for diagnosing a health condition of a patient, for establishing Hdp marker values or Hdp surrogate marker values for purposes of comparison with Hdp values of a patient is provided.
  • An Hdp monitor senses, measures, and records Hdp values exhibited by the patient during a basal or non-exposure period and furthermore Hdp values exhibited by the patient during or after an exposure period during which the patient is exposed to low-energy electromagnetic output signals.
  • An electrically-powered generator is adapted to be actuated to generate said low-energy electromagnetic carrier output signals for exposing or applying to the patient such output signals during said exposure period
  • FIG. 1 shows a block diagram of exemplary circuitry, exemplary of circuitry which may be employed as the variable Hdp variation means for application of electromagnetic output signals to a patient in accordance with the present invention.
  • FIG. 2 shows an example patient during experimental setup for continuous monitoring of hemodynamic parameters before and during AM RF EMF exposure in accordance with the present invention.
  • FIG. 3 is an example is eleven hemodynamic parameters simultaneously measured during each heartbeat:
  • FIG. 4 is a flow diagram representing a hemodynamic recording performed continuously during non-exposure and exposure periods in a double-blind fashion.
  • the present invention provides hemodynamic parameter (Hdp) monitoring system for diagnosing a health condition of a patient.
  • the system comprises a hemodynamic parameter Hdp monitor that senses and records various identified sensed Hdp values of the patient.
  • the system generally senses various identified sensed Hdp values of the patient utilizing electrodes placed in topical contact with various determined parts of the body.
  • the hemodynamic parameter Hdp monitor further comprises recording means that records the various identified sensed Hdp values of the patient.
  • the recording means can utilize any storage device on which the various identified sensed Hdp values of the patient can be recorded.
  • Hdp values For purposes of diagnosing a health condition of a patient, it has been determined for purposes of diagnoses performed in accordance with the invention, that a variety of Hdp values need to be sensed, measured and recorded, which include the values of at least the following nine Hdp's:
  • basal measurements or basal Hdp values are herein named basal measurements or basal Hdp values.
  • initial measurements of above parameters are performed on pre-diagnosed subjects after a period of relaxation, for example about 15 minutes, while the patient is lying in a supine position (face and preferably also palms of the hands facing upwardly).
  • the pre-diagnosed subjects are exposed to or application of an Hdp-influencing procedure involving exposure to or application of selected electromagnetic fields (EMF) output signals.
  • EMF electromagnetic fields
  • the above-mentioned EMF output signals may be provided by a generator device adapted to generate EMF output signals at certain predetermined amplitude modulation (AM) frequencies.
  • AM amplitude modulation
  • the subjects or patients are most preferably exposed to or the output signals are applied to patients during heart-beat times over a determined period of time, most preferably over the time of at least ten heart-beat times of the patient.
  • This procedure would in general take place while the patient remains connected to or is reconnected to the Hdp monitor of the system of the invention so that Hdp values may be sensed and measured during the period of exposure or application.
  • the Hdp values may, however, also or alternatively be sensed and measured after the period of exposures or applications, for purposes of determining potentially lasting effects, generally statistically significant therapeutically beneficial effects, of the exposures or applications to the patient.
  • Hdp values measured during or after above exposures or applications to pre-diagnosed subjects or patients are herein referred to as post-exposure or Hdp variation values.
  • the procedures above in general as applied to multiple patients pre-diagnosed to be suffering from an identified form of poor health condition, provide both multiple basal Hdp values and multiple post-exposure Hdp values as related to the identified pre-diagnosed form of poor health condition.
  • These multiple Hdp values may in general be somewhat scattered values. Accordingly, for purposes of defining representative marker Hdp values, such scattered values would regularly be analyzed by statistical procedures for purposes of obtaining representative Hdp values for each of the Hdp parameters.
  • Conventional statistical procedures might for example include Dixon's Q test employed for identifying and rejecting outlier values; a T-test for determining whether or not mean values of two groups of values are statistically different from one another; Fisher's discriminant analysis, standard deviation measures and variance values; and principle component analysis (PCA), a statistical procedure that uses an orthogonal transformation to convert a set of observations of possibly correlated variables into a set of values of linearly uncorrelated variables called principal components.
  • Values reported herein for Hdp values for various Hdp's employ a PCA of correlated variables to linearly uncorrelated variables (PC's).
  • Hdp values analyzed by such statistical procedures serve as markers for so-called surrogate markers employed for diagnosis of a health condition of a subject (including values for a healthy condition).
  • the surrogates in the present invention providing marker values would include numbers of patients pre-diagnosed to be either healthy or suffering from an identified form of a poor health condition, such as an identified form of cancer as mentioned below.
  • the Hdp monitoring system of the present invention provides means for establishing and identifying marker values for use in diagnosis of health conditions of a patient.
  • the marker values are termed surrogate markers in that the marker values are determined by the monitoring system following on treatments and Hdp value measurements performed on patients pre-diagnosed to be either healthy or suffering from a known form of poor health condition.
  • An Hdp monitor as described above is employed in conjunction with a generator device adapted to generate EM output signals at certain predetermined amplitude modulation (AM) frequencies determined to influence at least certain of the Hdp values of the Hdp's listed above.
  • the Hdp monitoring system of the invention should accordingly include means for sensing and measuring and recording both basal Hdp values and post-exposure Hdp values of patients.
  • the monitoring system of the invention may furthermore comprise stored information including surrogate markers as described above and comparison means for comparing representative measured Hdp values with representative surrogate markers as described below to provide the indicated diagnosis of a patient undergoing diagnosis.
  • the generator device may be adapted to receive sensed basal and post-exposure Hdp values from the Hdp monitor and comprise such stored information, which may, if desired, be communicated to the Hdp monitor to provide the attending medical staff with information concerning the indicated diagnosis.
  • Representative surrogate markers employed for diagnosis purposes are derived from computative combinations of information from both representative basal Hdp measured values and representative post-exposure or Hdp variance measured values. Since the predetermined AM frequencies employed for influencing Hdp values are different for each health condition and post exposure Hdp values are similarly different, the computative combinations for deriving representative surrogate markers for a specified health condition requires different computations, for example for purposes of aligning different forms of cancer in a PCA dual group analysis.
  • the reliability of marker values is of course dependent on the number of pre-diagnosed surrogates included for each type of poor health condition examined.
  • HCC Hepatocellular Carcinoma
  • the incidence of poor health conditions among populations, more particularly high incidence poor health conditions that are difficult to diagnose, such as Hepatocellular Carcinoma (HCC) or related liver diseases has received particular attention.
  • the relatively high incidence of breast cancer has thus far also received particular attention, as reported below.
  • Post-exposure or Hdp variance measured values insofar as may be reflected following on exposure to or application of low energy AM carrier signals, in terms of the invention, may be compared with Hdp values which occur following on exposure or application to a patient of predetermined AM frequency values predetermined to alleviate a cause of a specified poor health condition of a patient.
  • Matching basal and post-exposure Hdp values on their own, may both support the efficacy of treatment by application of said predetermined AM frequency values and provide a preliminary indication of diagnosis of the health condition of the patient.
  • the electrically powered generator of AM electromagnetic output signals at certain AM frequencies may comprise a storage device for storing predetermined AM frequency values.
  • Such storage device may be employed for controlling the AM frequencies of the output signals, as described in above-mentioned EP Application No. 08 734 777.9-1652.
  • the exposure or application of means for inducing Hdp value variances may comprise a variable AM frequency tuning device adapted to vary the AM frequencies between low and high limit values.
  • consecutive exposures or applications of sections of the range of AM frequencies may be required in order to identify AM frequency values at which post-application Hdp value variations actually occur during the heart-beat times at which Hdp values are sensed, measured and recorded by the Hdp monitor.
  • the system of the invention includes output signal frequency measurement and recording means for measuring and recording such frequency values at which frequencies Hdp variances of at least certain of the hemodynamic parameter values are exhibited.
  • Hdp value recording means for recording each of the measured values for each of the identified Hdp's, preferably separately of one another, measured and recorded before, during or after the period of time of exposure to or application of output signals to the patient.
  • a further component of the hemodynamic parameter monitoring system of the invention is an analyzer component which may be integrated with or coupled to the recording means for recording hemodynamic parameter values before, during or after performing or exposing the patient to a cellular excitation procedure.
  • the analyzer component may include program-controlled calculation means for performing statistical analyses of various of the recorded hemodynamic parameter values to obtain representative values for each of the different recorded hemodynamic parameter values, optionally making a determination of ratios between different representative hemodynamic parameter values, and comparing either or both of such representative values or ratios between different values, with predetermined representative values or ratios, predetermined in patients known to be healthy or to be suffering from or likely to develop an identified poor health condition.
  • the comparison of calculated representative values for recorded hemodynamic parameter values or ratios, more particularly so-called post-excitation hemodynamic parameter variation values, which match with predetermined representative hemodynamic parameter values or ratios, leads to providing an indication of a diagnosis of a health condition of a patient.
  • An analyzer component may, alternative or additional to being integrated or coupled to the recording means as described above, be located at an analysis center which may perform the analyses based on recorded hemodynamic parameter information received or communicated to the center.
  • the following Table 2 is exemplary Principal Component (PC) values, representative of a multiple number of sensed and recorded hemodynamic parameter values for each of the nine values of a number of patients.
  • the PC representative values are divided into three groups: Pressure, Flow and Beat for three groups each of 8 patients, respectively 8 patients with hepatocellular carcinoma (HCC), 8 patients with breast cancer, and 8 healthy controls for simplifying comparisons of PC Hdp values between patients with a diagnosis of HCC or breast cancer and healthy controls.
  • HCC hepatocellular carcinoma
  • HCC hepatocellular carcinoma
  • 8 healthy controls for simplifying comparisons of PC Hdp values between patients with a diagnosis of HCC or breast cancer and healthy controls.
  • Also included in the following Table is reference to X and Y canonical coordinates obtained by the Fisher's discriminant analysis, representative pressure, flow and beat PC values of Hdp's exhibited by patients before exposures or applications of EM AM signals:
  • Table 3 is exemplary discrimination by analytical geometry using canonical coordinates and vectors obtained from PC values, representative of a multiple number of sensed and recorded hemodynamic parameter values for each of the nine values of a number of patients.
  • the PC representative values are divided into three groups, Pressure, Flow and Beat for three groups each of the patients, respectively with HCC, patients with breast cancer, and healthy controls.
  • d_group of values using linear discriminant function of geometric parameters, the distinct group of patients based on their diagnosis is identified:
  • FIG. 1 a block diagram of exemplary circuitry, exemplary of circuitry which may be employed as the variable Hdp variation means for application of electromagnetic output signals to a patient is seen.
  • Such exemplary circuitry may be provided with connection means for connection to or may be comprised or integrated into in the hemodynamic parameter monitoring system of the invention. Descriptions of each of the blocks of the block diagram or functions thereof are included to facilitate an understanding thereof.
  • the block diagram of electronic circuitry of an application system applies AM RF output signals to a patient at predetermined selected AM frequencies.
  • the predetermined selected frequencies are controlled by AM frequency values stored in storage device 52 .
  • the stored predetermined AM frequency values are separately determined by biofeedback procedures performed on patients and stored in storage device 52 .
  • Various predetermined selected AM frequencies applied to a patient are indicated for treatment of patients suffering from one or other form of a poor health condition of a patient.
  • the present invention contemplates employing a device or modified device as described above or indeed other devices described in the art, such as described U.S. Pat. No. 5,690,692 assigned to Regeneration Technology of Tijuana, Mexico, in combination with a hemodynamic parameter monitoring system able to sense and measure at least the nine hemodynamic parameter values referred to above. More particularly, such a combination enables sensing of hemodynamic parameter values of a patient both prior to, during or after application to the patient of AM RF electromagnetic signals as described in prior literature or other such signals as may be applied to the patient. Of particular interest in this regard is that sensed, measured and recorded hemodynamic parameter (Hdp) values differ dependently of the patient condition.
  • Hdp hemodynamic parameter
  • sensed and recorded hemodynamic parameter values differ between patients suffering from different forms of cancer and differ from such values of healthy patient conditions. Moreover, it appears that such hemodynamic parameter values are shared, at least to a major extent, by patients suffering from the same or a closely related poor health condition.
  • the sensed and recorded hemodynamic parameter values accordingly offer diagnosis opportunities for diagnosing various forms of poor health conditions of a nature such as mentioned above and also diagnosis of healthy patient conditions.
  • variable frequency tuning device in combination with the hemodynamic parameter monitor, would enable sensing of Hdp values required in terms of the invention at various frequency values.
  • the frequency values may be selected from frequency values suggested in terms of prior disclosures for determining the effects on Hdp values or variations thereof. However, such frequency values at which Hdp values or variations thereof which are of interest may be recorded. Recorded frequency values may be compared to predetermined frequency values proposed in earlier disclosures for treatment of patients in support of the identity or accuracy thereof or may provide information related to additional frequency values which may provide beneficial therapeutic effects on patients suffering from a poor health condition.
  • the frequency signal is gradually increased at a predetermined rate from zero to a predetermined level controllable by a user.”
  • a predetermined rate from zero to a predetermined level controllable by a user.
  • U.S. Pat. No. 5,690,692 relies on predetermined frequency values for performing treatment procedures.
  • microprocessor 21 operates as the controller for the application system and is connected to control the various components of the system through address bus 22 , data bus 23 and input/output (I/O) lines 25 .
  • Microprocessor 21 preferably includes internal storage for the operation code, control program, and temporary data.
  • microprocessor 21 includes input/output (I/O) ports and internal timers.
  • Microprocessor 21 may, for example, be an 8-bit single-chip micro-controller, 8048 or 8051 available from Intel Corporation, 2200 Mission College Boulevard, Santa Clara, Calif. 95054 U.S.
  • the timing for microprocessor 21 is provided by system clock 24 which includes a clock crystal 26 along with capacitors 27 and 28 .
  • System clock 24 may run at any clock frequency suitable for the particular type of microprocessor used. In accordance with one embodiment, system clock 24 operates at a clock frequency of 8.0 MHz.
  • microprocessor 21 functions to control controllable electromagnetic energy generator circuit 29 to produce a desired form of modulated low energy electromagnetic emission for application to a patient through probe 13 .
  • Controllable generator circuit 29 includes modulation frequency generator circuit 31 and carrier signal oscillator 32 .
  • Microprocessor 21 operates to activate or de-activate controllable generator circuit 29 through oscillator disable line 33 .
  • Controllable generator circuit 29 also includes an AM modulator and power generator 34 which operates to amplitude modulate a carrier signal produced by carrier oscillator 32 on carrier signal line 36 , with a modulation signal produced by modulation signal generator circuit 31 on modulation signal line 37 .
  • Modulator 34 produces an amplitude modulated carrier signal on modulated carrier signal line 38 , which is then applied to the filter circuit 39 .
  • the filter circuit 39 is connected to probe 13 via coaxial cable 12 and impedance transformer 14 .
  • Microprocessor 21 controls modulation signal generator circuit 31 of controllable generator circuit 29 through address bus 22 , data bus 23 and I/O lines 25 .
  • microprocessor 21 selects the desired waveform stored in modulation waveform storage device 43 via I/O lines 25 .
  • Microprocessor 21 also controls waveform address generator 41 to produce on waveform address bus 42 a sequence of addresses which are applied to modulation signal storage device 43 in order to retrieve the selected modulation signal.
  • the desired modulation signal is retrieved from wave form look-up table 43 and applied to modulation signal bus 44 in digital form.
  • Modulation signal bus 44 is applied to digital to analog converter (DAC) 46 which converts the digital modulation signal into analog form.
  • DAC digital to analog converter
  • This analog modulation signal is then applied to selective filter 47 which, under control of microprocessor 21 , filters the analog modulation signal by use of a variable filter network including resistor 48 and capacitors 49 and 51 in order to smooth the wave form produced by DAC 46 on modulation signal line 20 .
  • look-up table 43 may contain up to 8 different modulation signal wave forms.
  • Wave forms which have been successfully employed include square wave forms or sinusoidal wave forms.
  • Other possible modulation signal wave forms include rectified sinusoidal, triangular, and combinations of all of the above.
  • each modulation signal wave form uses 256 bytes of memory and is retrieved from look-up table 43 by running through the 256 consecutive addresses.
  • the frequency of the modulation signal is controlled by how fast the wave form is retrieved from look-up table 43 .
  • this is accomplished by downloading a control code from microprocessor 21 into programmable counters contained within wave form address generator 41 .
  • the output of the programmable counters then drive a ripple counter that generates the sequence of 8-bit addresses on the wave form address bus 42 .
  • Wave form address generator 41 may, for example, be a programmable timer/counter uPD65042C, available from NEC.
  • Modulation signal storage device or look-up table 43 may, for example, be a type 28C16 Electrical Erasable Programmable Read Only Memory (EEPROM) programmed with the desired wave form table.
  • Digital to analog converter 46 may, for example, be a DAC port, AD557JN available from Analog Devices, and selective filter 47 may be a type 4052 multiplexer, available from National Semiconductor or Harris Semiconductor.
  • application storage device 52 may be any storage device capable of storing information for later retrieval.
  • application storage device 52 may be, for example, a magnetic media based storage device such as a card, tape, disk, or drum.
  • application storage device 52 may be a semiconductor memory-based storage device such as an erasable programmable read only memory (EPROM), an electrical erasable programmable read only memory (EEPROM) or a non-volatile random access memory (RAM).
  • EPROM erasable programmable read only memory
  • EEPROM electrical erasable programmable read only memory
  • RAM non-volatile random access memory
  • Another alternative for application storage device 52 is a mechanical information storage device such as a punched card, cam, or the like.
  • Yet another alternative for application storage device 52 is an optical storage device such as a compact disk read only memory (CD ROM).
  • microprocessor 21 separate from application storage device 52
  • microprocessor 21 and application storage device 52 may both be incorporated into a single device, which is loaded into the system to control the operation of the system as described herein.
  • interface 16 would exist between the combination of microprocessor 21 and application storage device 52 and the rest of the system.
  • Interface 16 is configured as appropriate for the particular application storage device 52 in use. Interface 16 translates the control information stored in application storage device 52 into a usable form for storage within the memory of microprocessor 21 to enable microprocessor 21 to control controllable generator circuit 29 to produce the desired modulated low energy emission. Interface 16 may directly read the information stored on application storage device 52 , or it may read the information through use of various known communications links. For example, radio frequency, microwave, telephone or optical based communications links may be used to transfer information between interface 16 and application storage device 52 . When application storage device 52 and microprocessor 21 are incorporated in the same device, interface 16 is configured to connect microprocessor 21 to the rest of system.
  • the control information stored in application storage device 52 specifies various controllable parameters of the modulated low energy RF electromagnetic emission which is applied to a patient through probe 13 .
  • controllable parameters include, for example, the frequency and amplitude of the carrier, the amplitudes and frequencies of the modulation of the carrier, the duration of the emission, the power level of the emission, the duty cycle of the emission (i.e., the ratio of on time to off time of pulsed emissions applied during an application), the sequence of application of different modulation frequencies for a particular application, and the total number of treatments and duration of each treatment prescribed for a particular patient.
  • the carrier signal and modulation signal may be selected to drive the probe 13 with an amplitude modulated signal in which the carrier signal includes spectral frequency components below 1 GHz, and preferably between 1 MHz and 900 MHz, and in which the modulation signal comprises spectral frequency components between 0.1 Hz and 10 KHz, and preferably between 1 Hz and 150 KHz.
  • the modulation signal may be sequenced to form the modulation signal.
  • an electromagnetic emission sensor 53 may be provided to detect the presence of electromagnetic emissions at the frequency of the carrier oscillator 32 .
  • Emission sensor 53 provides to microprocessor 21 an indication of whether or not electromagnetic emissions at the desired frequency are present.
  • Microprocessor 21 then takes appropriate action, for example, displaying an error message on information output display 17 , disabling controllable generator circuit 29 , or the like.
  • the invention also includes a power sensor 54 which detects the amount of power applied to the patient through probe 13 compared to the amount of power returned or reflected from the patient. This ratio is indicative of the proper use of the system during a therapeutic session.
  • Power sensor 54 applies to microprocessor 21 through power sense line 56 an indication of the amount of power applied to patient through probe 13 relative to the amount of power reflected from the patient.
  • the indication provided on power sense line 56 may be digitized and used by microprocessor 21 , for example, to detect and control a level of applied power, and to record on application storage device 52 , information related to the actual treatments applied. Such information may then be used by a physician or other clinician to assess patient treatment compliance and effect.
  • treatment information may include, for example: the number of treatments applied for a given time period; the actual time and date of each treatment; the number of attempted treatments; the treatment compliance (i.e., whether the probe was in place or not in place during the treatment session); and the cumulative dose of a particular modulation frequency.
  • the level of power applied is preferably controlled to cause the specific absorption rate (SAR) of energy absorbed by the patient to be from 1 microwatt per kilogram of tissue to 50 Watts per kilogram of tissue.
  • the power level is controlled to cause an SAR of from 100 microwatts per kilogram of tissue to 10 Watts per kilogram of tissue.
  • the power level is controlled to deliver whole body mean SAR in the range of only 0.2 to 1 mW/kg, with a 1 g peak spatial SAR between 150 and 350 mW/kg These SARs may be in any tissue of the patient.
  • the system also includes powering circuitry including battery and charger circuit 57 and battery voltage change detector 58 .
  • tumor-specific frequencies have anti-proliferative effects on cancer cells, modulate the expression of genes involved in cell migration and invasion, and are capable of disrupting the mitotic spindle.
  • the clinical activity of these tumor-specific frequencies was assessed in two separate studies in which patients were treated with intrabuccally administered AM RF EMF, which were modulated at tumor-specific frequencies.
  • Antitumor activity was observed in patients with metastatic breast cancer (Barbault, A. et al. (2009)) and advanced hepatocellular carcinoma (Costa, F. P. et al. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.
  • British Journal of Cancer 105, 640-648 (2011) and stable disease was observed in patients with other tumor types.
  • the patient's diagnosis and the nature of AM RF EMF exposure were disclosed before computational analysis.
  • the validation group consisted of 25 patients with biopsy-proven cancer (11 with advanced HCC and 14 with advanced breast cancer), and 31 healthy controls.
  • the last group consisted of six patients with potentially resectable HCC
  • the discovery group consisted of eight patients with advanced hepatocellular carcinoma, six patients with advanced breast cancer, and six healthy controls; 2)
  • the validation group consisted of 25 patients with a diagnosis of cancer (14 female patients with advanced breast cancer and 11 male patients with advanced HCC) and 31 healthy controls (18 females and 13 males); and 3) six patients (five males and one female) with potentially resectable hepatocellular carcinoma.
  • the AM RF EMF device used for this study has been described in detail previously. (Costa, F. P. et al. British journal of cancer 105, 640-648 (2011)). While patients receiving treatment with AM RF EMF are exposed to three daily one hour treatments, the diagnostic feasibility of AM RF EMF administration was tested during a single 10 minute exposure in order to expose all individuals once to each of the 194 tumor-specific frequencies (HCC specific and breast cancer specific), which are each emitted for three seconds. (Barbault, A. et al. J. Exp. Clin. Cancer Res. 28, 51, doi:10.1186/1756-9966-28-51 (2009); Zimmerman, J. W. et al. British Journal of Cancer 106, 307-313 (2012); Costa, F. P.
  • FIG. 2 an example patient is seen during experimental setup for continuous monitoring of hemodynamic parameters before and during AM RF EMF exposure.
  • Non-invasive hemodynamic measurement was performed using a Task Force® Monitor (CNSystems Medizintechnik GmbH, version 2.2.12.0, Reininghausstra ⁇ e 13, 8020 Graz, Austria).
  • Numerical values of heart rate, blood pressure and blood flow are measured by digital photoplethysmography, pressure cuff and ECG.
  • the hemodynamic parameters are transformed into absolute values for each consecutive heartbeat before and during AM RF EMF exposure.
  • the spoon-shaped antenna for intrabuccal administration of AM RF EMF was placed in the patient's mouth during the entire experiment.
  • the Task Force® monitor is labelled 1 .
  • the AM RF EMF emitting device is labelled 2 .
  • the AM RF EMF emitting device connected to a coaxial cable, which is connected to the spoon-shaped antenna 3 .
  • a right arm digital pressure cuff is labelled 4 .
  • a digital photoplethysmography is labelled 5 .
  • a left arm digital pressure cuff is labelled; 6 . Electrodes' cables for ECG and impedance cardiography are provided.
  • hemodynamic parameters simultaneously measured during each heartbeat: heart rate (HR), systolic blood pressure (sBP), median blood pressure (mBP), diastolic blood pressure (dBP), total peripheral resistance (TPR), total peripheral resistance index (TPRI), cardiac output (CO), cardiac index (CI), RR interval (RRI), stroke volume (SV), and systolic index (SI).
  • HR heart rate
  • sBP systolic blood pressure
  • mBP median blood pressure
  • dBP diastolic blood pressure
  • TPR total peripheral resistance
  • TPRI total peripheral resistance index
  • CO cardiac output
  • CI cardiac index
  • RRI stroke volume
  • SI stroke volume
  • hemodynamic recording was performed continuously during non-exposure and exposure periods in a double-blind fashion.
  • the non-exposure periods were the initial basal and five minute resting intervals between RF EMF exposures.
  • patients received AM RF EMF (HCC-specific, breast cancer-specific, randomly chosen frequencies).
  • Hemodynamic parameters were analyzed according to three factors: diagnosis (HCC, breast cancer, healthy control), gender, and recording period (baseline and exposure to HCC-specific, breast cancer-specific, and randomly chosen modulation frequencies).
  • Hemodynamic parameter analysis during the basal non-exposure period revealed four different hemodynamic patterns in the discovery group.
  • the patient's diagnosis correlated with hemodynamic pattern in 5 (83.3%) of six cases of male HCC, 5 (83.3%) of six cases of female breast cancer and six (100.0%) of six healthy controls, seen in Table 4:
  • the HCC-specific hemodynamic response pattern was identified in 10 (90.0%) of 11 cases of HCC patients (Table 4).
  • the breast cancer-specific hemodynamic response pattern was identified in 12 (85.7%) of 14 female patients with breast cancer, as seen in Table 7:
  • the identification and characterization of new methods allowing for the diagnosis of hepatocellular carcinoma and breast cancer in a blinded fashion based solely on hemodynamic parameters measured before and during exposure to 27.12 MHz RF EMF amplitude modulated at tumor-specific frequencies are provided. These findings may have broad clinical implications for the diagnosis of cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Electromagnetism (AREA)
  • Signal Processing (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
US14/545,377 2015-04-28 2015-04-28 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient Abandoned US20160317050A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US14/545,377 US20160317050A1 (en) 2015-04-28 2015-04-28 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
EP16786952.8A EP3288448A4 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
US15/569,312 US10624546B2 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
SG11201903784PA SG11201903784PA (en) 2015-04-28 2016-04-22 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
SG10201910005Q SG10201910005QA (en) 2015-04-28 2016-04-22 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
PCT/US2016/028880 WO2016176117A1 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
CN201680038230.4A CN108064147B (zh) 2015-04-28 2016-04-22 用于诊断患者的健康状况的血流动力学参数（hdp）监视系统
JP2018508612A JP7036712B2 (ja) 2015-04-28 2016-04-22 患者の健康状態の診断用の血行動態パラメータ（ｈｄｐ）監視システム
HK18110471.7A HK1250899A1 (zh) 2015-04-28 2018-08-15 用於診斷患者的健康狀況的血流動力學參數(hdp)監視系統
US16/594,625 US20200268258A1 (en) 2015-04-28 2019-10-07 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
US16/853,173 US11589765B2 (en) 2015-04-28 2020-04-20 Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
US18/175,021 US20230218188A1 (en) 2015-04-28 2023-02-27 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/545,377 US20160317050A1 (en) 2015-04-28 2015-04-28 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2016/028880 Continuation WO2016176117A1 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
US15/569,312 Continuation US10624546B2 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
US201916277455A Continuation 2015-04-28 2019-02-15

Publications (1)

Publication Number Publication Date
US20160317050A1 true US20160317050A1 (en) 2016-11-03

Family

ID=57199487

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/545,377 Abandoned US20160317050A1 (en) 2015-04-28 2015-04-28 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
US15/569,312 Active 2035-08-03 US10624546B2 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
US16/594,625 Abandoned US20200268258A1 (en) 2015-04-28 2019-10-07 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
US16/853,173 Active US11589765B2 (en) 2015-04-28 2020-04-20 Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
US18/175,021 Pending US20230218188A1 (en) 2015-04-28 2023-02-27 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient

Family Applications After (4)

Application Number Title Priority Date Filing Date
US15/569,312 Active 2035-08-03 US10624546B2 (en) 2015-04-28 2016-04-22 Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
US16/594,625 Abandoned US20200268258A1 (en) 2015-04-28 2019-10-07 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient
US16/853,173 Active US11589765B2 (en) 2015-04-28 2020-04-20 Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
US18/175,021 Pending US20230218188A1 (en) 2015-04-28 2023-02-27 Hemodynamic parameter (hdp) monitoring system for diagnosis of a health condition of a patient

Country Status (7)

Country Link
US (5) US20160317050A1 (zh)
EP (1) EP3288448A4 (zh)
JP (1) JP7036712B2 (zh)
CN (1) CN108064147B (zh)
HK (1) HK1250899A1 (zh)
SG (2) SG11201903784PA (zh)
WO (1) WO2016176117A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112413A1 (en) * 2016-12-15 2018-06-21 Costa Frederico Perego System for characterization, diagnosis, and treatment of a health condition of a patient and methods of using same
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego SYSTEM FOR CHARACTERIZING, DIAGNOSING AND PROCESSING A PATIENT'S HEALTH STATUS AND MICROTUBULAR CONDUCTIVITY, AND METHODS OF USING THE SAME
WO2020097129A1 (en) * 2018-11-05 2020-05-14 Autem Medical, Llc Chemical exchange saturation transfer system for characterization, diagnosis, and treatment of a health condition
US20200229711A1 (en) * 2019-01-17 2020-07-23 Grant Hocking Method to Quantify the Hemodynamic and Vascular Properties in Vivo from Arterial Waveform Measurements
US11464440B2 (en) 2019-04-10 2022-10-11 Autem Medical, Llc System for prognosticating patient outcomes and methods of using the same
US11589765B2 (en) 2015-04-28 2023-02-28 Therabionic, Inc. Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601539A (zh) * 2017-08-24 2020-08-28 S·科日瑙 一种自动诊断对象病症的方法及实施该方法的系统

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441528A (en) * 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
US20030139678A1 (en) * 1999-06-10 2003-07-24 Harbinger Medical, Inc. Method of noninvasively determining a patient's susceptibility to arrhythmia
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US20070173908A1 (en) * 2006-01-20 2007-07-26 Cyberonics, Inc. Transcutaneous trigeminal nerve stimulation to treat motion sickness
US20080221419A1 (en) * 2005-12-08 2008-09-11 Cardio Art Technologies Ltd. Method and system for monitoring a health condition
US20120019711A1 (en) * 2004-10-01 2012-01-26 The Board Of Trustees Of The Leland Stanford Junior Univeristy Imaging arrangements and methods therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611166A (pt) * 1995-10-11 1999-04-06 Regeneration Tech Processo e gerador de freqüência bioativa
US5983141A (en) 1996-06-27 1999-11-09 Radionics, Inc. Method and apparatus for altering neural tissue function
FR2845294B1 (fr) 2002-10-04 2005-06-24 Ela Medical Sa Dispositif medical implantable actif tel que stimulateur cardiaque, defibrillateur, cardioverteur et/ou dispositif mutisite, comprenant des moyens de determination d'un indice hemodynamique moyen
TWI225394B (en) 2003-05-14 2004-12-21 Bo-Jau Guo Method and device for analysis of heart rate variability (HRV)
AU2006325153B2 (en) 2005-11-29 2013-03-28 PhysIQ Inc. Residual-based monitoring of human health
EP1974769A1 (en) 2007-03-27 2008-10-01 Boris Pasche Electronic system for influencing cellular functions in a warm-blooded mammalian subject
DE102007017486B4 (de) 2007-04-13 2009-03-05 Ekra Automatisierungssysteme Gmbh Asys Group Vorrichtung und Verfahren zum Bearbeiten von flächigen Substraten, wie zum Bedrucken von Leiterplatten oder dergleichen
CN102202568A (zh) * 2008-05-12 2011-09-28 心脏技术有限公司 集成心脏监测设备和使用集成心脏监测设备的方法
US8989837B2 (en) * 2009-12-01 2015-03-24 Kyma Medical Technologies Ltd. Methods and systems for determining fluid content of tissue
WO2010129513A2 (en) * 2009-05-05 2010-11-11 Robert Peter Blankfield Evaluation of stroke volume differential as it relates to cardiovascular health
US8971998B2 (en) * 2009-12-31 2015-03-03 Integral Electromagnetronic Technologies Llc Systems and methods for multispectral scanning and detection for medical diagnosis
SG183435A1 (en) 2010-03-15 2012-09-27 Singapore Health Serv Pte Ltd Method of predicting the survivability of a patient
WO2011135297A1 (en) * 2010-04-30 2011-11-03 Lidco Group Plc Monitoring device and method
KR101565000B1 (ko) 2010-10-07 2015-11-02 바이오모비 코프 원격 치료 시스템
CN103006185B (zh) * 2012-12-19 2015-06-17 中国人民解放军第四军医大学 一种非接触磁感应电阻抗平面投影成像装置及方法
US10024756B2 (en) 2014-10-28 2018-07-17 Embraer S.A. Method and system for structural health monitoring with frequency synchronization
US20160317050A1 (en) 2015-04-28 2016-11-03 Federico Perego Costa Hemodynamic parameter (Hdp) monitoring system for diagnosis of a health condition of a patient
WO2018112413A1 (en) 2016-12-15 2018-06-21 Costa Frederico Perego System for characterization, diagnosis, and treatment of a health condition of a patient and methods of using same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441528A (en) * 1992-09-25 1995-08-15 Symtonic, S.A. Method and system for applying low energy emission therapy
US20030139678A1 (en) * 1999-06-10 2003-07-24 Harbinger Medical, Inc. Method of noninvasively determining a patient's susceptibility to arrhythmia
US20050143779A1 (en) * 2003-12-24 2005-06-30 Cardiac Pacemakers, Inc. Baroreflex modulation based on monitored cardiovascular parameter
US20120019711A1 (en) * 2004-10-01 2012-01-26 The Board Of Trustees Of The Leland Stanford Junior Univeristy Imaging arrangements and methods therefor
US20080221419A1 (en) * 2005-12-08 2008-09-11 Cardio Art Technologies Ltd. Method and system for monitoring a health condition
US20070173908A1 (en) * 2006-01-20 2007-07-26 Cyberonics, Inc. Transcutaneous trigeminal nerve stimulation to treat motion sickness

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11589765B2 (en) 2015-04-28 2023-02-28 Therabionic, Inc. Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
WO2018112413A1 (en) * 2016-12-15 2018-06-21 Costa Frederico Perego System for characterization, diagnosis, and treatment of a health condition of a patient and methods of using same
WO2019075391A1 (en) 2017-10-13 2019-04-18 Costa Frederico Perego SYSTEM FOR CHARACTERIZING, DIAGNOSING AND PROCESSING A PATIENT'S HEALTH STATUS AND MICROTUBULAR CONDUCTIVITY, AND METHODS OF USING THE SAME
EP3694409A4 (en) * 2017-10-13 2021-06-23 Autem Medical, LLC SYSTEM FOR THE CHARACTERIZATION, DIAGNOSIS AND TREATMENT OF A PATIENT'S HEALTH AND MICROTUBULES CONDUCTIVITY, AND METHODS FOR USING SUCH SYSTEM
WO2020097129A1 (en) * 2018-11-05 2020-05-14 Autem Medical, Llc Chemical exchange saturation transfer system for characterization, diagnosis, and treatment of a health condition
EP3876832A4 (en) * 2018-11-05 2022-08-17 Autem Medical, LLC CHEMICAL EXCHANGE SATURATION TRANSFER SYSTEM FOR CHARACTERIZATION, DIAGNOSIS AND TREATMENT OF A HEALTH CONDITION
US20200229711A1 (en) * 2019-01-17 2020-07-23 Grant Hocking Method to Quantify the Hemodynamic and Vascular Properties in Vivo from Arterial Waveform Measurements
US11464440B2 (en) 2019-04-10 2022-10-11 Autem Medical, Llc System for prognosticating patient outcomes and methods of using the same
EP3952735A4 (en) * 2019-04-10 2023-01-11 Autem Medical, LLC PATIENT OUTCOME PROGNOSTIC SYSTEM AND METHODS OF USE

Also Published As

Publication number Publication date
HK1250899A1 (zh) 2019-01-18
JP7036712B2 (ja) 2022-03-15
EP3288448A1 (en) 2018-03-07
CN108064147A (zh) 2018-05-22
SG10201910005QA (en) 2019-11-28
JP2018518331A (ja) 2018-07-12
US20230218188A1 (en) 2023-07-13
CN108064147B (zh) 2021-09-03
US11589765B2 (en) 2023-02-28
WO2016176117A1 (en) 2016-11-03
SG11201903784PA (en) 2019-05-30
US20180338689A1 (en) 2018-11-29
EP3288448A4 (en) 2019-01-02
US20200268258A1 (en) 2020-08-27
US10624546B2 (en) 2020-04-21
US20200315466A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US11589765B2 (en) Hemodynamic parameter (HDP) monitoring system for diagnosis of a health condition of a patient
Kusayama et al. Simultaneous noninvasive recording of electrocardiogram and skin sympathetic nerve activity (neuECG)
US20180296099A1 (en) System for characterization, diagnosis, and treatment of a health condition of a patient and methods of using same
Yoshida et al. The value of defibrillator electrograms for recognition of clinical ventricular tachycardias and for pace mapping of post-infarction ventricular tachycardia
ES2390924T3 (es) Programador y método asociado para su uso en la selección de vectores de detección con un dispositivo médico implantable
US20130096448A1 (en) Methods and apparatus for enhanced fiducial point determination and non-invasive hemodynamic parameter determination
US20040087838A1 (en) Meridian linking diagnostic and treatment system and method for treatment of manifested and latent maladies using the same
TW200829208A (en) Medical instrument
Goudman et al. Effects of spinal cord stimulation on heart rate variability in patients with failed back surgery syndrome: comparison between a 2-lead ECG and a wearable device
Ahn et al. Electrodermal measures of Jing-Well points and their clinical relevance in endometriosis-related chronic pelvic pain
Zachariah et al. Significance of abnormal and late ventricular signals in ventricular tachycardia ablation of ischemic and nonischemic cardiomyopathies
US9629559B2 (en) Measuring homeostatic risk
US20230346289A1 (en) System for prognosticating patient outcomes and methods of using the same
Hashimoto et al. Diurnal variation of frequency domain T‐wave alternans on 24‐hour ambulatory electrocardiogram in subjects without heart disease: Significant effect of autonomic nervous activity of the heart
US20170224232A1 (en) Measuring homeostatic risk
BR112017023157B1 (pt) Sistema de monitoramento de parâmetros hemodinâmicos (hdp) para diagnosticar um estado de saúde de um paciente e método para diagnósticar um estado de saúde de um paciente
US11911178B2 (en) System and method to detect and treat arrhythmogenic regions in atrial fibrillation
Besleaga et al. Real Time Non-Invasive Hemodynamic Assessment of Ventricular Tachycardia
RU2106855C1 (ru) Способ рефлексотерапии и устройство для его осуществления
Xu et al. Preexcitation syndrome: experimental study on the electrocardiogram of antegradely conducting accessory pathway
RU2211658C1 (ru) Способ суточного кардиомониторирования для определения наличия и активности заболеваний человека неинфекционной природы
Lazim et al. Development and Validation of Heart Rate-incorporated Finger Photoplethysmography Fitness Index Algorithm for Cardiovascular Disease Risk Assessment
Vavrinsky et al. Combination of electro/impedance/seismo/phono cardiography in medicine
Swerdlow et al. The Future of the Implantable Cardioverter-Defibrillator
JP2023500073A (ja) 人体内の医学的に能動的なインプラントを検出するための装置及び方法

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: AVATAR PARTNERS LIMITED, VIRGIN ISLANDS, BRITISH

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COSTA, FREDERICO PEREGO;REEL/FRAME:052447/0246

Effective date: 20200302

AS Assignment

Owner name: THERABIONIC, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVATAR PARTNERS LIMITED;REEL/FRAME:052688/0038

Effective date: 20200513